NO20032503D0 - Fenyletenyl- eller fenyletynylderivater som glutamatreseptorantagonister - Google Patents
Fenyletenyl- eller fenyletynylderivater som glutamatreseptorantagonisterInfo
- Publication number
- NO20032503D0 NO20032503D0 NO20032503A NO20032503A NO20032503D0 NO 20032503 D0 NO20032503 D0 NO 20032503D0 NO 20032503 A NO20032503 A NO 20032503A NO 20032503 A NO20032503 A NO 20032503A NO 20032503 D0 NO20032503 D0 NO 20032503D0
- Authority
- NO
- Norway
- Prior art keywords
- phenylethenyl
- receptor antagonists
- glutamate receptor
- phenylethynyl
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00126615 | 2000-12-04 | ||
PCT/EP2001/013714 WO2002046166A1 (en) | 2000-12-04 | 2001-11-26 | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20032503L NO20032503L (no) | 2003-06-03 |
NO20032503D0 true NO20032503D0 (no) | 2003-06-03 |
NO324326B1 NO324326B1 (no) | 2007-09-24 |
Family
ID=8170567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20032503A NO324326B1 (no) | 2000-12-04 | 2003-06-03 | Fenyletenyl- eller fenyletynylderivater som glutamatreseptorantagonister, deres anvendelse til fremstilling av medikamenter for behandling eller forebygging av sykdommer |
Country Status (32)
Country | Link |
---|---|
US (4) | US6706707B2 (no) |
EP (1) | EP1349839B8 (no) |
JP (2) | JP4077317B2 (no) |
KR (1) | KR100515549B1 (no) |
CN (1) | CN1257894C (no) |
AR (1) | AR035401A1 (no) |
AT (1) | ATE288898T1 (no) |
AU (2) | AU2956702A (no) |
BG (1) | BG107877A (no) |
BR (1) | BR0115871A (no) |
CA (1) | CA2430696C (no) |
CZ (1) | CZ20031795A3 (no) |
DE (1) | DE60108900T2 (no) |
DK (1) | DK1349839T3 (no) |
EC (1) | ECSP034640A (no) |
ES (1) | ES2248410T3 (no) |
HK (1) | HK1063318A1 (no) |
HR (1) | HRP20030429A2 (no) |
HU (1) | HUP0400570A3 (no) |
IL (2) | IL155999A0 (no) |
MA (1) | MA26971A1 (no) |
MX (1) | MXPA03004862A (no) |
NO (1) | NO324326B1 (no) |
NZ (1) | NZ525917A (no) |
PL (1) | PL366222A1 (no) |
PT (1) | PT1349839E (no) |
RS (1) | RS43903A (no) |
RU (1) | RU2284323C9 (no) |
SI (1) | SI1349839T1 (no) |
SK (1) | SK8402003A3 (no) |
WO (1) | WO2002046166A1 (no) |
ZA (1) | ZA200303870B (no) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0128996D0 (en) * | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
WO2004014881A2 (en) | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
EP1581525A2 (en) | 2002-08-09 | 2005-10-05 | AstraZeneca AB | Compounds having an activity at metabotropic glutamate receptors |
MXPA05001592A (es) * | 2002-08-09 | 2005-05-05 | Astrazeneca Ab | Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico. |
ITMI20030151A1 (it) * | 2003-01-30 | 2004-07-31 | Recordati Ind Chimica E Farma Ceutica S P A | Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore. |
PT1603877E (pt) | 2003-03-04 | 2009-02-11 | Addex Pharma Sa | Novos derivados de aminopiridina como antagonistas de mglur5 |
JP4610480B2 (ja) | 2003-03-07 | 2011-01-12 | アステラス製薬株式会社 | 2,6−ジ置換スチリルを有する含窒素ヘテロ環誘導体 |
TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
JP2006521358A (ja) * | 2003-03-26 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体のベンズアミドモジュレータ |
UA80888C2 (en) | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
WO2005118568A1 (en) * | 2004-06-01 | 2005-12-15 | F. Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
WO2004111040A1 (en) * | 2003-06-12 | 2004-12-23 | F. Hoffmann-La Roche Ag | Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists |
US7915424B2 (en) * | 2004-03-22 | 2011-03-29 | Eli Lilly And Company | Pyridyl derivatives and their use as mGlu5 antagonists |
MY149038A (en) * | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
KR101057032B1 (ko) * | 2004-06-01 | 2011-08-16 | 에프. 호프만-라 로슈 아게 | Mglu5 수용체 길항제로서 피리딘-4-일-에틴일-이미다졸및 피라졸 |
GB0413605D0 (en) | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
DE102004044884A1 (de) * | 2004-09-14 | 2006-05-24 | Grünenthal GmbH | Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen |
KR20070083781A (ko) | 2004-10-26 | 2007-08-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물의 비정질체 |
WO2006071730A1 (en) * | 2004-12-27 | 2006-07-06 | Astrazeneca Ab | Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders |
CA2602444C (en) | 2005-03-23 | 2013-03-19 | F.Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists |
GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
EP1950211A4 (en) * | 2005-11-18 | 2011-08-31 | Eisai R&D Man Co Ltd | PROCESS FOR PREPARING A CINEMA ACID AMID DERIVATIVE |
JPWO2007058304A1 (ja) * | 2005-11-18 | 2009-05-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物の塩またはそれらの溶媒和物 |
BRPI0618814A2 (pt) * | 2005-11-24 | 2014-04-29 | Eisai R&D Man Co Ltd | Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
US20070142477A1 (en) * | 2005-12-19 | 2007-06-21 | The University Of Liverpool | Analgesia |
DE102005062985A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln |
MX2008011221A (es) * | 2006-03-09 | 2008-09-11 | Eisai R&D Man Co Ltd | Compuestos de cinamida policiclicos. |
TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
DE102006011574A1 (de) | 2006-03-10 | 2007-10-31 | Grünenthal GmbH | Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln |
AR062095A1 (es) * | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
KR101148580B1 (ko) | 2006-12-21 | 2012-05-24 | 에프. 호프만-라 로슈 아게 | Mglur5 수용체 길항제의 다형체 |
US20080207900A1 (en) | 2007-02-28 | 2008-08-28 | Teiji Kimura | Two cyclic oxomorphorin derivatives |
CA2687262A1 (en) * | 2007-05-16 | 2008-11-20 | Naoyuki Shimomura | One-pot production process for cinnamide derivative |
CL2008002542A1 (es) * | 2007-08-31 | 2009-01-02 | Eisai R&D Man Co Ltd | Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
EP2239265A1 (en) * | 2008-01-28 | 2010-10-13 | Eisai R&D Management Co., Ltd. | Crystalline cinnamide compounds or salts thereof |
US8323805B2 (en) | 2009-06-04 | 2012-12-04 | Nitto Denko Corporation | Emissive aryl-heteroaryl acetylenes |
US8334287B2 (en) | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
JPWO2012015024A1 (ja) * | 2010-07-29 | 2013-09-12 | 大正製薬株式会社 | エチニル−ピラゾール誘導体 |
HUE040156T2 (hu) * | 2010-11-05 | 2019-02-28 | Oat Agrio Co Ltd | Etinilfenilamidinvegyület vagy sója, eljárás azok elõállítására, és fungicid mezõgazdasági és kertészeti alkalmazásra |
WO2012172093A1 (en) * | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
KR101291037B1 (ko) * | 2011-10-12 | 2013-08-01 | 사회복지법인 삼성생명공익재단 | 레스베라트롤 유도체와 스티릴-오각형 방향족 화합물 및 이들의 베타-아밀로이드 플라그에 대한 결합제 및 진단영상제의 용도 |
WO2017117708A1 (en) * | 2016-01-05 | 2017-07-13 | Hua Medicine (Shanghai) Ltd. | Pyrazole derivatives |
EP3440054B1 (en) * | 2016-04-06 | 2021-12-01 | Hua Medicine (Shanghai) Ltd. | Pyrrole derivatives useful as mglur5 modulators |
US11083199B2 (en) | 2017-01-10 | 2021-08-10 | Bayer Aktiengesellschaft | Heterocycle derivatives as pesticides |
AU2018310881C1 (en) | 2017-07-31 | 2021-12-16 | Novartis Ag | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
CN114746408A (zh) * | 2019-12-02 | 2022-07-12 | 豪夫迈·罗氏有限公司 | 炔基-(杂芳基)-甲酰胺hcn1抑制剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3303199A (en) | 1963-07-15 | 1967-02-07 | Geigy Chem Corp | Certain imidazolone derivatives and process for making same |
US3341548A (en) | 1964-04-29 | 1967-09-12 | Hoffmann La Roche | Nitroimidazoles and their preparation |
DE2035905A1 (de) * | 1970-07-20 | 1972-02-03 | Chemische Fabrik Stockhausen & Cie.,4150Krefeld | Imidazolverbindungen und deren Herstellungsverfahren |
CA1174673A (en) | 1981-02-27 | 1984-09-18 | Walter Hunkeler | Imidazodiazepines |
US4711962A (en) | 1984-10-18 | 1987-12-08 | Stauffer Chemical Company | Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles |
SG52709A1 (en) | 1989-06-30 | 1998-09-28 | Du Pont | Substituted imidazoles |
US5821937A (en) * | 1996-02-23 | 1998-10-13 | Netsuite Development, L.P. | Computer method for updating a network design |
TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
CA2297732C (en) * | 1997-08-14 | 2008-04-29 | F. Hoffmann-La Roche Ag | Heterocyclic vinylethers against neurological disorders |
US6377987B1 (en) * | 1999-04-30 | 2002-04-23 | Cisco Technology, Inc. | Mechanism for determining actual physical topology of network based on gathered configuration information representing true neighboring devices |
AU780009B2 (en) * | 1999-08-31 | 2005-02-24 | Merck Sharp & Dohme Corp. | Heterocyclic compounds and methods of use thereof |
-
2001
- 2001-11-26 AU AU2956702A patent/AU2956702A/xx active Pending
- 2001-11-26 ES ES01990437T patent/ES2248410T3/es not_active Expired - Lifetime
- 2001-11-26 SI SI200130304T patent/SI1349839T1/xx unknown
- 2001-11-26 KR KR10-2003-7007421A patent/KR100515549B1/ko not_active IP Right Cessation
- 2001-11-26 JP JP2002547905A patent/JP4077317B2/ja not_active Expired - Fee Related
- 2001-11-26 AT AT01990437T patent/ATE288898T1/de active
- 2001-11-26 CA CA002430696A patent/CA2430696C/en not_active Expired - Fee Related
- 2001-11-26 SK SK840-2003A patent/SK8402003A3/sk unknown
- 2001-11-26 IL IL15599901A patent/IL155999A0/xx unknown
- 2001-11-26 WO PCT/EP2001/013714 patent/WO2002046166A1/en active IP Right Grant
- 2001-11-26 EP EP01990437A patent/EP1349839B8/en not_active Expired - Lifetime
- 2001-11-26 AU AU2002229567A patent/AU2002229567B2/en not_active Ceased
- 2001-11-26 NZ NZ525917A patent/NZ525917A/en unknown
- 2001-11-26 HU HU0400570A patent/HUP0400570A3/hu unknown
- 2001-11-26 RS YU43903A patent/RS43903A/sr unknown
- 2001-11-26 MX MXPA03004862A patent/MXPA03004862A/es active IP Right Grant
- 2001-11-26 PL PL01366222A patent/PL366222A1/xx unknown
- 2001-11-26 DK DK01990437T patent/DK1349839T3/da active
- 2001-11-26 CN CNB018199933A patent/CN1257894C/zh not_active Expired - Fee Related
- 2001-11-26 BR BR0115871-6A patent/BR0115871A/pt not_active Application Discontinuation
- 2001-11-26 CZ CZ20031795A patent/CZ20031795A3/cs unknown
- 2001-11-26 PT PT01990437T patent/PT1349839E/pt unknown
- 2001-11-26 RU RU2003119548/04A patent/RU2284323C9/ru not_active IP Right Cessation
- 2001-11-26 DE DE60108900T patent/DE60108900T2/de not_active Expired - Lifetime
- 2001-11-28 US US09/996,641 patent/US6706707B2/en not_active Expired - Fee Related
- 2001-12-03 AR ARP010105602A patent/AR035401A1/es unknown
-
2003
- 2003-03-25 US US10/396,172 patent/US6972299B2/en not_active Expired - Fee Related
- 2003-04-04 US US10/407,929 patent/US6927232B2/en not_active Expired - Fee Related
- 2003-05-19 IL IL155999A patent/IL155999A/en not_active IP Right Cessation
- 2003-05-19 ZA ZA200303870A patent/ZA200303870B/en unknown
- 2003-05-26 HR HR20030429A patent/HRP20030429A2/hr not_active Application Discontinuation
- 2003-06-03 NO NO20032503A patent/NO324326B1/no not_active IP Right Cessation
- 2003-06-03 EC EC2003004640A patent/ECSP034640A/es unknown
- 2003-06-04 MA MA27192A patent/MA26971A1/fr unknown
- 2003-06-04 BG BG107877A patent/BG107877A/bg unknown
-
2004
- 2004-08-13 HK HK04106082A patent/HK1063318A1/xx not_active IP Right Cessation
-
2005
- 2005-01-18 US US11/037,904 patent/US20050131043A1/en not_active Abandoned
-
2007
- 2007-12-17 JP JP2007325072A patent/JP2008169206A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20032503D0 (no) | Fenyletenyl- eller fenyletynylderivater som glutamatreseptorantagonister | |
DK1309559T3 (da) | 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister | |
DE60134762D1 (de) | Metabotropische glutamatrezeptor-antagonisten | |
DK1224175T3 (da) | Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister | |
DK1175401T3 (da) | Piperazinderivater, der er nyttige som CCR5-antagonister | |
DK1383750T3 (da) | Urinstofderivater som integrin a4 antagonister | |
NO20021459L (no) | Piperazin-derivater som 5-HT1B-antagonister | |
NO20030471D0 (no) | Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor | |
DK1305319T3 (da) | 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister | |
ATE318259T1 (de) | Selektive neurokinin-antagonisten | |
NO20032142D0 (no) | Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister | |
DK1170288T3 (da) | Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister | |
NO20025136D0 (no) | Cykloheksylaminderivat som subtype selektive NMDA- reseptorantagonister | |
NO20023293D0 (no) | Piperidin- og piperazinderivater som virker som 5-HT2A- reseptorantagonister | |
DK1068202T3 (da) | 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister | |
DK1360184T3 (da) | Piperidinderivater som neurokinin-1-antagonister | |
ATE492535T1 (de) | 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren | |
NO20044373L (no) | Azetidinderivater som CCR-3-reseptorantagonister | |
NO20004144D0 (no) | Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister | |
DE60224221D1 (de) | Aminotetralinderivate, antagonisten von muscarinrezeptoren | |
DK1176144T3 (da) | Nye N-triazolylmethyl-piperazinderivater som neurokininreceptor-antagonister | |
NO20014356L (no) | Bifenylderivater som antagonister av neurokinin-1 reseptoren | |
DK1086093T3 (da) | Tetrahydroquinolinderivater som glycinantagonister | |
NO20002575D0 (no) | Substituerte oksimer som neurokininantagonister | |
DK1077942T3 (da) | Carboxysubstituerede carboxamidderivater som tachykininreceptorantagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |